

Curriculum Vitae

Howard I. Schwartz, M.D., FACP, FAGA

Professional Experience

2025 - Present	Chief Medical Officer and Founder NextPhase Research Florida Hollywood, FL
2021 - Present	President and Chief Executive Officer Crestview Recovery Center, Asheville, NC
06/2018 - Present	President and CEO Dream Life Recovery Donegal, Philadelphia
06/2017 - Present	President and CEO My psychiatrist South Florida
12/2017 - 07/2023	Chief Medical Officer/Principal Investigator CenExel Research Centers of America Hollywood, Florida
01/2016 - 01/2019	Managing Director Monarch Specialty Group Miami, Florida
07/2015 - 08/2016	Clinical Trial Lead Miami Cancer Center Miami, Florida
10/1996 - 06/2015	President Miami Research Associates Miami, Florida
12/2012 - 06/2015	Chief Medical Officer QPS Holdings
1989 - 2018	Gastroenterologist Gastro Health Miami, Florida
2007 - 2015	President and Founder Sleep Florida Florida
2000 - 2012	Medical Director and Founder Miami Nutrition & Weight Loss Miami, Florida

Education and Post Graduate Training

1984	Doctor of Medicine University of Miami School of Medicine Miami, FL
1987 - 1989	Residency Jackson Memorial Hospital, Miami, Florida Gastroenterology Fellowship
1984 - 1987	Residency Jackson Memorial Hospital, Miami, Florida Medical Residency

Certifications

State of Florida Department of Health
Medical Doctor
License # ME 47067

Past Research Affiliation

CenExel Research Centers of America at Fort Lauderdale Behavioral Health Center
5757 N. Dixie Hwy
Oakland Park, FL 33334

CenExel Research Centers of America
7261 Sheridan Street, Suite 210
Hollywood, FL 33024

Professional Licensure

State of Florida Medical Doctor ME 103007

State of Florida DEA Registration FV4508505 / FV1117793

Affiliations

Dreamlife Recovery

Crestview Recovery

Fellow, American College of Physicians

Member, American College of Gastroenterology

American Gastroenterology Association

Publications

“Efficacy and Safety of Mrna-1273 SARS-CoV-2 Vaccine”, The New England Journal of Medicine, 2020.

Rater Certification and Scales Experience

Abnormal Involuntary Movement Scale (AIMS)

Barnes Akathisia Rating Scale (BAS)
Brief Psychiatric Rating Scale (BPRS)
Calgary Depression Scale for Schizophrenia (CDSS)
Children's Depression Rating Scale (CDRS)
Clinical Global Impression Severity/Improvement (CGI-S/I)
Clinician's Interview Based Impression of Change (CIBIC)
Clinical Opiate Withdrawal Scale (COWS)
Columbia Suicide Severity Rating Scale (C-SSRS)
Extrapyramidal Symptom Rating Scale (ESRS)
Global Assessment of Functioning (GAF)
Global Assessment Scale (GAS)
Hamilton Anxiety Rating Scale (HAM-A)
Hamilton Depression Rating Scale (HAM-D)
Inventory of Depressive Symptomatology-30 (IDS-30)
Kiddie - Positive and Negative Syndrome Scale (Kiddie PANSS)
Kiddie - Schedule for Affective Disorders and Schizophrenia (K-SADS)
Mini International Neuropsychiatric Interview (MINI/MINI-Kid)
Mini-Mental State Examination (MMSE)
Modified Himmelsbach Opioid Withdrawal Scale (MHOWS)
Montgomery-Asberg Depression Rating Scale (MADRS)
Negative Symptoms Assessment-16 (NSA-16)
Personal and Social Performance Scale (PSP)
Positive and Negative Syndrome Scale (PANSS)
Schedule for Affective Disorders and Schizophrenia - Change (SADS-C)
Simpson-Angus Scale (SAS)
Structured Clinical Interview for DSM-IV Axis I Disorder (SCID)
Young Mania Rating Scale (YMRS)

Clinical Research Experience

2022 Merck: An Open-Label, Single-Dose Clinical Study to Evaluate the Pharmacokinetics of XXXX in Participants with Moderate Hepatic Impairment.

2022: Phase 3, randomized, 28-day, double-blind, placebo-controlled, multicenter study to assess the safety and efficacy of XXXX in subjects with acute exacerbation of schizophrenia trial, followed by a 52-week open-label extension.

2022: Double-blind, placebo-controlled, randomized withdrawal study to evaluate XXXX physical dependence in adult subjects with schizophrenia.

2022 Prothena: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of PRX012 in Healthy Volunteers and Patients with Alzheimer's Disease.

2022 Novavax: A Randomized, Observer-Blinded, Phase 3 Study to Compare the Safety, and Immunogenicity of 3 Lots of XXXX in Adults; IND.

2022 Pfizer: A Phase 3, Randomized, Observer-Blinded Study to Evaluate the Relative Safety, Tolerability, Efficacy, and Immunogenicity of a modified XXXX vaccine against influenza compared to a licensed Inactivated Influenza Vaccine in Healthy Adults >65 Years of Age study.

2022 Neurogastrx: A Phase 3 Randomized, Double-blind, Active-controlled, Parallel-Group Study of the safety and efficacy of XXXX administered Orally to Participants with Erosive Esophagitis.

2022 Alnylam: A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of XXXX in Patients with Mild-to-Moderate Hypertension.

2022 Moderna: Exploratory study to assess the use of wearable digital sensors after mRNA vaccination in healthy adults.

2022 Moderna: Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified XXXX Vaccines Using a Systems Biology Approach in Healthy Adults.

2022 Sanofi: A Phase I, parallel, randomized, active-controlled, multi-center, dose-escalation study with early safety data reviews to assess safety and immunogenicity of a monovalent XXXX vaccine encoding influenza hemagglutinin in adults 18 years of age and older.

2022 Vaxcyte: A Phase 2, Randomized, Observer-Blind, Dose-Finding, Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine XXXX in Healthy Adults 65 Years and Older.

2022 Moderna: Phase 1/2, randomized, stratified, observer-blind study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1073 (SARS-CoV-2 and influenza vaccine) compared to co-administered XXXXXX (influenza) and mRNA-1273 (SARS-CoV-2) vaccines and to mRNA-1010 vaccine and XXXXX vaccine alone in healthy adults 18-75 years of age.

2022 Otonomy: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Safety Study of a Single-Dose of OTO-313 Given as a Single Unilateral or Bilateral Intratympanic Injection in Subjects with Subjective Tinnitus.

2022 Lundbeck: Interventional, randomized, double-blind, placebo-controlled, single-ascending-dose study investigating the safety, tolerability, and pharmacokinetic properties of Lu AF87908 in healthy subjects and patients with Alzheimer's disease.

2022 Pfizer: A Phase 1, Open-Label, Randomized, Single Dose, 2-Way Crossover Study Assessing Pharmacokinetic Comparability of two XXXX Presentation, On-Body Injector and Prefilled Syringe, In Healthy Participants.

2022 Vaxcyte: A Phase 1/2a Randomized, Observer-Blind, Dose-Finding, Controlled, Parallel-Group, Two-Stage Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine in Healthy Adults Aged 18 to 64 Years.

2022 Apnimed: Phase 2 Randomized Double-Blind Placebo-Controlled Parallel-Arm Dose Finding Study to Compare Fixed Dose Combinations of XXXX and XXXX to XXXX alone or Placebo in Obstructive Sleep Apnea.

2022 Moderna: A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults.

2021: Randomized, double-blind (patient, investigator), placebo-controlled, dose-escalation study on safety, tolerability, pharmacokinetic and preliminary efficacy of XXXX as adjunctive therapy in patients with major depressive disorder after single oral dosing.

2021: Randomized, double-blind, placebo-controlled, parallel-group study of XXXX for the prevention of relapse in patients with schizophrenia.

2021: Double-blind, placebo-controlled, randomized dose-ranging trial to investigate efficacy and safety of intravenous XXXX infusion in addition to comprehensive standard of care on the rapid reduction of symptoms of Major Depressive Disorder in subjects who have suicidal ideation with intent.

2021: Two-part Phase 2 study to assess the efficacy, safety, and tolerability of XXXX administered to adults with major depressive disorder at imminent risk of suicide.

2021: Randomized, single-blind, two-period crossover to investigate the effect of XXXX on the Pharmacokinetics of Metformin in subjects with schizophrenia.

2021: Phase 3, randomized, observer-blind study to evaluate the lot consistency, safety, tolerability, and immunogenicity of the vaccine XXXX against COVID-19 in healthy adults 18 through 55 years of age.

2021 Otonomy: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of OTO-313 Given as a single Intratympanic Injection in Subjects with Unilateral Subject Tinnitus.

2021 Otonomy: A Randomized, Double-Blind, Placebo-Controlled Phase 1/2 Study of OTO-413 Given as a Single Intratympanic Injection in Subjects with Speech-In-Noise Hearing Impairment.

2021 Janssen: A Double-Blind, Placebo-Controlled, Randomized, Multipart, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered JNJ-75220795.

2021 Pfizer: A Phase 1, Open-Label, Fixed-Sequence, 2-Period Study to Estimate the Effect of Multiple Dose Abrocitinib on The Pharmacokinetics of Single Doses of Caffeine, Efavirenz, And Omeprazole in Healthy Participants.

2021 Pfizer: A Phase 1, Open-Label, 3-Treatment, 6-Sequence, 3 Period Crossover Study to Estimate the Effect of PF-07321332/XXXXXXXXXX and XXXXXXXXXX on the Pharmacokinetics of Dabigatran in Healthy Participants.

2021 Moderna: A Phase 2, randomized, stratified, observer-blind study to evaluate the immunogenicity and XXXX, XXXX, and XXXX vaccines for SARS-CoV-2.

2021 Moderna: A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARSCoV2 Variants.

2021 Sanofi: Immunogenicity and Safety of SARS-CoV-2 Recombinant Protein Vaccines with AS03 Adjuvant in Adults 18 Years of Age and Older as a Primary Series and Immunogenicity and Safety of a Booster Dose of SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (two Monovalent and one Bivalent).

2021 Sanofi: Safety and Immunogenicity of a First In-Human Influenza XXXX Vaccine in Healthy Adults Aged 18 to 49 Years.

2021 GSK: A Phase III, randomized, open-label, controlled, multi-center study to evaluate the immune response and safety of both herpes zoster subunit vaccine in healthy adults aged 50 years and older AND the influenza virus vaccine in healthy adults aged 18 years and older when administered sequentially or co-administered with XXXX booster vaccination.

2021 GSK: First-Time-in Human (FTiH), randomized, observer-blind, placebo-controlled, dose escalation study to assess safety, reactogenicity and immunogenicity of a candidate cytomegalovirus (CMV) vaccine comprising recombinant protein and adjuvant when administered intramuscularly in healthy adults.

2021 Medicago: A Randomized, Observer-Blind, Placebo-Controlled, Phase 2/3 Study to Assess the Safety, Efficacy, and Immunogenicity of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults 18 Years of Age or Older.

2021 Moderna: A Phase 1/2 , Randomized, Stratified, Observer-Blind, Dose Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-XXXX Seasonal Influenza Vaccine in Healthy Adults 18 Years and Older.

2021 Janssen: A Randomized, Double-blind, Phase 2 Study to Evaluate the Immunogenicity, Reactogenicity and Safety of XXXX Administered as Booster Vaccination in Adults 18 Years if Age and Older Who Have Previously Received Primary Vaccination with XXXX or XXXX.

2021 Janssen: A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Immunogenicity and Safety of Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadministration, in Adults Aged 65 Years and Older.

2021 Pfizer: A phase 3, randomized, double-blind trial to describe the safety and immunogenicity of 20-valent pneumococcal conjugate vaccine when coadministered with a booster dose of XXXX in adults 65 years of age and older.

2021 Pfizer: A Phase 3 Master Protocol to Evaluate Additional Dose(S) of XXXX in Healthy Adults Previously Vaccinated with XXXX.

2021 Eisai: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 2-Period, Crossover Study to Evaluate the Respiratory Safety of XXXX in Adult and Elderly Subjects With Moderate to Severe Obstructive Sleep Apnea and Adult and Elderly Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease.

2021 Pfizer: A Phase 1, Randomized, Open-Label, Cross-Over, Single-Dose Study to Evaluate the Bioequivalence of Candidate Capsule Formulations of XXXXXXXX to Tablets and Estimate the Effect of High-Fat Meal on Bioavailability in Healthy Participants.

2021 Merck: A Clinical Trial to Study the Effect of a Single Dose of XXXXX (XX) on the Pharmacokinetics of Methadone.

2021 Pfizer: A Phase 3, Randomized, Observer-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Lyophilized formulation of the vaccine candidate XXXX against COVID-19 in Healthy Adults 18 Through 55 Years of Age.

2021 Pfizer: A Phase 3, Randomized, Observer-Blind Study to Evaluate the Safety, Tolerability, And Immunogenicity of Multiple Production Lots and Dose Levels of the Vaccine Candidate XXXX Against COVID-19 In Healthy Participants 12 Through 50 Years of Age.

2021 Intra-Cellular: An Open-label Multiple Dose Study to Determine the Pharmacokinetics, Safety, and Tolerability of XXXXX in Patients, Ages 13 to 17 Years, Diagnosed with Schizophrenia or Schizoaffective Disorder.

2021 Kymera: A Phase 1 randomized, placebo-controlled, single and multiple ascending dose trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of orally administered KT 474 in healthy adult volunteers and patients with atopic dermatitis (AD) or hidradenitis suppurativa (HS).

2020: Phase 3, randomized, double-blind, parallel-group, placebo-controlled, multicenter study to evaluate the efficacy and safety of XXXX in acutely psychotic hospitalized adults with DSM-5 schizophrenia.

2020: Open-label extension study to assess the long-term safety, tolerability and efficacy of XXXX in subjects with DSM-5 schizophrenia.

2020: Phase 2B placebo/active-controlled XXXX in schizophrenia.

2020: A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of iloperidone for 4 weeks in the treatment of patients with acute manic episodes associated with Bipolar I Disorder.

2020: Phase 1/2/3, placebo-controlled, randomized, observer-blind, dose-finding study to evaluate the safety, tolerability, immunogenicity, and efficacy of sars-cov-2 XXXX vaccine candidates against covid-19 in healthy individuals.

2020: Randomized, subject and investigator-blinded, placebo controlled, cross-over, multi-center Proof of Concept (PoC) study to assess the wakefulness promoting effect, safety, tolerability, and pharmacokinetics of XXXX in shift work disorder (SWD) patients.

2020: Phase 1, open-label, randomized, single ascending dose trial to determine the pharmacokinetics, safety, and tolerability of XXXX long acting injectable in adult subjects with schizophrenia.

2020: Phase 1, open-label, randomized, single ascending dose trial to determine the pharmacokinetics, safety, and tolerability of XXXX long acting injectable in adult subjects with schizophrenia.

2020 Janssen: A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of XXXX for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older.

2020 Novavax: A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) with Matrix-M1™ Adjuvant in Adult Participants ≥ 18 Years with a Pediatric Expansion in Adolescents (12 to < 18 Years).

2020 Sanofi: Immunogenicity and Safety of SARS-CoV-2 Recombinant Protein Vaccine Formulations (with or without adjuvant) in Healthy Adults 18 Years of Age and Older.

2020 Merck: A Phase 1/Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Safety, Tolerability and Immunogenicity of XXXX (COVID-19 Vaccine) in Healthy Younger and Older Participants.

2020 Pfizer: A Phase 1/2 Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding Study to describe the safety, Tolerability, Immunogenicity, and Potential Efficacy of SARS-CoV-2 RNA Vaccine Candidates Against COVID-19 in Healthy Adults ('Study') to be conducted at the Institution under the Pfizer Protocol identified above ('Protocol').

2020 Moderna: A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older.

2020 Lundbeck: Interventional, randomized, double-blind, sequential-group, placebo-controlled, single-ascending-dose study investigating the safety, tolerability and pharmacokinetic and pharmacodynamic properties of Lu AF82422 in healthy non-Japanese and Japanese subjects and in patients with Parkinson's disease.

2020 Seqirus: A Phase 2, Randomized, Stratified, Observer-Blind Clinical Study to Evaluate Safety and Immunogenicity of the MF59-Adjuvanted Quadrivalent Subunit Inactivated Cell-derived Influenza Vaccine (XXXX) in adults ≥50 years of age.

2020 Imbrium: A Phase 2, Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of XXXX in Subjects with an Alcohol Use Disorder who are Experiencing Insomnia Associated with Alcohol Cessation.

2020 Takeda: A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Crossover Study of a Single Intravenous Infusion Dose of TAK-925 in Patients With Idiopathic Hypersomnia.

2020 Sanofi: Safety and Efficacy of 4 Investigational HSV-2 Vaccines Administered by Intramuscular Route in Adults with Recurrent Genital Herpes Caused by HSV-2.

2020 Phathom: A Phase 3, Randomized, Double-Blind, Two-Phase, Multicenter Study to Evaluate the Efficacy and Safety of Vonoprazan 20 mg Compared to Lansoprazole 30 mg for Healing in Patients with Erosive Esophagitis and to Evaluate the Efficacy and Safety of Vonoprazan (10 mg and 20 mg) Compared to Lansoprazole 15 mg for the Maintenance of Healing in Patients with Healed Erosive Esophagitis.

2020 Phathom: A Phase 3 Randomized Multicenter Study to Evaluate the Efficacy and Safety of Open-Label Dual Therapy with Oral Vonoprazan 20 mg or Double-Blind Triple Therapy with Oral Vonoprazan 20 mg Compared to Double-Blind Triple Therapy with Oral Lansoprazole 30 mg Daily in Patients with Helicobacter Pylori Infection.

2020 Sanofi: Safety and Immunogenicity of an Investigational Meningococcal Group B Vaccine in Healthy Adults.

2020 Otsuka: A Phase 1b, Multicenter, Open-label, Multiple Ascending Dose Trial to Assess the Pharmacokinetics, Safety and Tolerability of Centanafadine Extended-release Capsules after Oral Administration in Pediatric Subjects (4 to 12 years, inclusive) with Attention-deficit/Hyperactivity Disorder.

2020 Sage: A Phase 3 Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating The Efficacy Of Sage-217 In The Treatment of Adult Subjects with Major Depressive Disorder.

2020 Supernus: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Flexible-Dose Study of the Efficacy and Safety of SPN-812 in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD).

2020 Supernus: An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of SPN-812 in Adults with Attention-Deficit/Hyperactivity Disorder.

2020 Jazz: A 12-Week, Double-blind, Placebo-controlled, Randomized, Parallel-Group, Multicenter Study of the Efficacy and safety of XXXX (XXXX) to Improve Wakefulness in Adult Patients with Excessive Daytime Sleepiness Associated with Major Depressive Disorder with a 40-Week Open-Label Safety Extension and Randomized withdrawal Period.

2019: Lot consistency trial of XXXX for anthrax prophylaxis.

2019: Major depressive disorder trial of XXXX.

2019: Acute suicidal ideation in bipolar depression study.

2019: Non-alcoholic fatty liver disease study of XXXX + XXXX.

2019: XXXX in acutely psychotic schizophrenia patients.

2019 Merck: A Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral MK-8591 Once-Monthly in Participants at Low-Risk for HIV-1 Infection.

2019 FluGen: Phase Ib clinical study to investigate the safety and immunogenicity of the Bris I0 (A/Brisbane/10/2007) M2SR and Sing2016 (A/Singapore/INFIMH-16-0019/2016) M2SR H3N2 monovalent influenza vaccines.

2019 Novavax: A Phase 3, Randomized, Observer-Blinded, Active-Controlled Trial to Evaluate the Immunogenicity and Safety of a Recombinant Quadrivalent Nanoparticle Influenza Vaccine (Quad-NIV) with Matrix-M1™ Adjuvant Against Fluzone® Quadrivalent in Clinically Stable Adults ≥ 65 Years of Age.

2019 Astellas: A Phase 1/2, Randomized, Single Ascending Dose Study in Adults (Stage 1) and Randomized, Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects with ASP3772, a Pneumococcal Vaccine.

2019 Satsuma: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine.

2019 Emergent: A Phase 3, Randomized, Double-blind, Parallel-group Trial to Evaluate the Lot Consistency, Immunogenicity, and Safety of AV7909 for Postexposure Prophylaxis of Anthrax in Healthy Adults.

2019 Merck: A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older.

2019 Merck: A Phase 1/Phase 2, Randomized, Double-blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine in Adults.

2019 Pfizer: A Phase 3, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of A 20-Valent Pneumococcal Conjugate Vaccine-Naïve Adults 18 Years of Age and Older.

2019 Sanofi: Safety and Immunogenicity of Quadrivalent Recombinant Influenza Vaccine Formulations Containing Different H3 Hemagglutinin Antigens in Healthy Adult Subjects 18 to 30 Years of Age.

2019 Moderna: A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 When Administered to Healthy Adults.

2019 Axsome: MOMENTUM (Maximizing Outcomes in Treating Acute Migraine): A Randomized, Double-blind, Single-dose, Placebo-controlled Study to Assess the Efficacy and Safety of AXS-07 (meloxicam and rizatriptan) for the Acute Treatment of Migraine in Adults.

2019 Sage: A Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, and Efficacy of XXXX Compared to Placebo in Adult Subject with Comorbid Major Depression Disorder and Insomnia.

2018 Idorsia: Multi-center, double-blind, randomized, placebo-controlled, parallel-group, polysomnography study to assess the efficacy and safety of ACT-541468 in adult and elderly subjects with insomnia.

From 1992 to 2014, Dr. Howard Schwartz has served as Principal Investigator or Sub-Investigator on more than 1000 clinical trials across a wide range of therapeutic areas including vaccines, infectious diseases, CNS, psychiatry, neurology, gastroenterology, metabolic disorders, and oncology. His early contributions began in gastrointestinal research, followed by extensive leadership in large-scale vaccine development programs including pivotal studies on influenza, RSV, Ebola, anthrax, HPV, and COVID-19, as well as groundbreaking Phase I trials in psychiatric disorders, insomnia, Alzheimer's disease, and chronic pain. His decades of experience span early-phase through post-marketing studies, positioning him as a trusted partner to pharmaceutical sponsors and CROs globally.